Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05412472 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419
A Phase 1 study, sponsored by Galera Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT05412472 is a Phase 1 study that has completed, run by Galera Therapeutics. The registered enrollment target is 26 participants.
The verdict
NCT05412472, a Phase 1 study, has completed, sponsored by Galera Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The study is a two-center, Phase 1, open-label, single-dose, one-period, four groups, PK study in subjects with various severities of renal impairment and matched healthy controls.
Interventions
- DRUG GC4419
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-04-04 |
| Est. Completion | 2021-04-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05412472
The ClinicalTrials.gov registry entry for NCT05412472 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galera Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GC4419 is the first listed.
NCT05412472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05412472 about?
NCT05412472 is a clinical study titled "Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419". The study is a two-center, Phase 1, open-label, single-dose, one-period, four groups, PK study in subjects with various severities of renal impairment and matched healthy controls.
What is the current status of trial NCT05412472?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2019-04-04. Estimated completion is 2021-04-06.
What interventions are being tested in trial NCT05412472?
The interventions under investigation include: GC4419 (DRUG).
Who is sponsoring clinical trial NCT05412472?
This trial is sponsored by Galera Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.